Ocular Therapeutix (NASDAQ:OCUL) Sets New 12-Month High at $7.05

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating)’s share price reached a new 52-week high on Tuesday . The company traded as high as $7.05 and last traded at $6.87, with a volume of 514542 shares traded. The stock had previously closed at $6.51.

Wall Street Analyst Weigh In

OCUL has been the topic of a number of recent analyst reports. HC Wainwright reduced their price objective on shares of Ocular Therapeutix from $11.00 to $10.00 in a research report on Tuesday, May 9th. JMP Securities increased their price objective on shares of Ocular Therapeutix from $11.00 to $12.00 in a research report on Tuesday, May 9th. Robert W. Baird initiated coverage on shares of Ocular Therapeutix in a research report on Thursday, April 20th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, StockNews.com lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.80.

Ocular Therapeutix Trading Down 4.2 %

The firm has a market capitalization of $516.32 million, a PE ratio of -5.60 and a beta of 1.31. The stock’s 50-day moving average price is $5.73 and its 200 day moving average price is $4.54. The company has a debt-to-equity ratio of 5.63, a current ratio of 3.61 and a quick ratio of 3.53.

Ocular Therapeutix (NASDAQ:OCUL – Get Rating) last issued its earnings results on Monday, March 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. The business had revenue of $14.08 million for the quarter, compared to analyst estimates of $13.60 million. Ocular Therapeutix had a negative net margin of 171.85% and a negative return on equity of 213.57%. On average, sell-side analysts expect that Ocular Therapeutix, Inc. will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Ocular Therapeutix

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Ocular Therapeutix by 0.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 206,249 shares of the biopharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 1,720 shares in the last quarter. FMR LLC boosted its stake in shares of Ocular Therapeutix by 84.4% during the first quarter. FMR LLC now owns 4,751 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 2,175 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Ocular Therapeutix by 61.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 9,225 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,500 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Ocular Therapeutix by 13.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 34,873 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 4,045 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Ocular Therapeutix by 22.2% during the fourth quarter. Principal Financial Group Inc. now owns 24,566 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 4,471 shares in the last quarter. 55.40% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

(Get Rating)

Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.